The Life Sciences and Public M&A teams advised Guggenheim Securities as financial advisor to Pfizer Inc.(NYSE: PFE) in the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners.
The Goodwin team was led by Stuart Cable, James Matarese, Blake Liggio and Caitlin Tompkins.
For additional details on the acquisition, please read the press release.